pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
siRNA · news · pharmadog
← back to siRNA
News · siRNA
111
stories
Sep 25, 26
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
Sep 24, 26
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
Sep 23, 26
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 21, 26
ADARx targets $319M IPO as TRexBio, Retension join filing queue
endpoints
Sep 15, 26
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
Sep 11, 26
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
Sep 11, 26
Novartis drags peers down with triple asset stumble
biospace
Sep 11, 26
Novartis drags peers down with triple asset failure
biospace
Sep 10, 26
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
Sep 8, 26
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
biospace
Sep 8, 26
Moonwalk raises $70M to test siRNA treatment for obesity
endpoints
Sep 8, 26
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
Sep 6, 26
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 5, 26
AbbVie-allied ADARx aims for IPO with three drugs in the clinic
endpoints
Sep 3, 26
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
biospace
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Aug 31, 26
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
fiercebiotech
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
fiercebiotech
Aug 14, 26
Capricor soars on potential FDA review extension, filing amendments
biospace
Aug 13, 26
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
Aug 11, 26
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
Aug 11, 26
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
Aug 10, 26
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
Aug 10, 26
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
Aug 10, 26
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
Aug 5, 26
STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AI
stat
← prev
page 3 of 4
next →